# Junta clínica — PT-pseudo_11fe9c6ca833 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_11fe9c6ca833",
  "pid": "PT-pseudo_11fe9c6ca833",
  "task": 1,
  "psa": 190.0,
  "age": 66,
  "months": 2,
  "pirads": "5",
  "psad": 4.097,
  "psav": 41.57,
  "psap": 125.1,
  "vol": 46.38,
  "dre": "Nodus",
  "bx": "Positive",
  "cspca": 0.9718793,
  "medhx": "Hypertension, Coronary artery disease",
  "meds": "valsartan, lisinopril, metoprolol, aspirin 80 mg",
  "notes": "PSA 190 ng/mL. PI-RADS 5. PSAD 4.10. Prostate volume 46 mL. DRE nodus. csPCa 0.97.",
  "pmhx": [
    "Hypertension",
    "Coronary artery disease"
  ],
  "allergies": [],
  "vitals": {
    "weight": "61 kg",
    "height": "167 cm",
    "bmi": "21.9",
    "bp": "125/89 mmHg",
    "hr": "77 bpm",
    "smoking": "Ex-smoker (10 pack-yr, quit 2022)",
    "last_dental": "6 mo ago",
    "flu_vax": "Sep 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "02 Feb 2025",
  "enc_ref": "Dr. E. Mulder (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Clinical attention was requested due to a prostate-specific antigen measurement of 190.0 ng/mL and a prior biopsy-proven prostate cancer."
    },
    {
      "s": "History",
      "t": "A 66-year-old civil engineer resides with his partner, balancing a biweekly tennis regimen with moderate alcohol intake. Clinical consultation was sought to reassess a previously established prostate malignancy following a positive prior biopsy, now accompanied by a prostate-specific antigen level of 190.0 ng/mL. Urinary complaints include an IPSS score of 14/35, driven mainly by nocturia and a diminished stream, though hematuria and acute retention are absent. Systemic history encompasses hypertension and coronary artery disease, stabilized during his most recent cardiology visit, and managed pharmacologically with valsartan, lisinopril, metoprolol, and aspirin 80 mg. Tobacco use ceased in 2022 after a cumulative 10 pack-year exposure. A recent chest radiograph showed no abnormalities. Commuting over an hour via rail, he specifically requested extended consultation time."
    },
    {
      "s": "Physical examination",
      "t": "DRE — texture: firm with an irregular nodule situated in the left peripheral zone, while the surrounding tissue remains symmetrically enlarged yet non-tender. General vitals show a blood pressure of 125/89 mmHg alongside a regular cardiac rhythm at 77 beats per minute. Peripheral lymph nodes and abdominal organs reveal no enlargement or masses."
    }
  ],
  "occupation": "civil engineer",
  "marital": "Married",
  "living": "Lives with partner",
  "next_of_kin": "Spouse / partner (primary contact)",
  "recent_other": [
    "Radiology — chest X-ray (routine)"
  ],
  "alcohol": "4 units / week",
  "exercise": "Tennis 2x/week",
  "ipss": "IPSS score: 14/35 (moderate LUTS)",
  "admin": "Patient travels 60+ min by train to clinic; allow buffer.",
  "mri_hospital": "Spaarne Gasthuis (Haarlem)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_11fe9c6ca833
Task: 1

Encounter: Urology - outpatient on 02 Feb 2025.
Referrer: Dr. E. Mulder (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 66-year-old male
  - PSA: 190.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 4.097 ng/mL²
  - PSA velocity: 41.57 ng/mL/yr
  - Prior PSA: 125.1 ng/mL
  - Prostate volume: 46.38 mL
  - Months since last PSA: 2
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.9718793 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, Coronary artery disease
  - Problem list / PMHx: Hypertension, Coronary artery disease
  - Current medication: valsartan, lisinopril, metoprolol, aspirin 80 mg
  - Allergies: NKA
  - Additional notes: PSA 190 ng/mL. PI-RADS 5. PSAD 4.10. Prostate volume 46 mL. DRE nodus. csPCa 0.97.

Vitals: weight 61 kg, height 167 cm, BMI 21.9, BP 125/89 mmHg, HR 77 bpm. Smoking: Ex-smoker (10 pack-yr, quit 2022).

Chief complaint: Clinical attention was requested due to a prostate-specific antigen measurement of 190.0 ng/mL and a prior biopsy-proven prostate cancer.

History: A 66-year-old civil engineer resides with his partner, balancing a biweekly tennis regimen with moderate alcohol intake. Clinical consultation was sought to reassess a previously established prostate malignancy following a positive prior biopsy, now accompanied by a prostate-specific antigen level of 190.0 ng/mL. Urinary complaints include an IPSS score of 14/35, driven mainly by nocturia and a diminished stream, though hematuria and acute retention are absent. Systemic history encompasses hypertension and coronary artery disease, stabilized during his most recent cardiology visit, and managed pharmacologically with valsartan, lisinopril, metoprolol, and aspirin 80 mg. Tobacco use ceased in 2022 after a cumulative 10 pack-year exposure. A recent chest radiograph showed no abnormalities. Commuting over an hour via rail, he specifically requested extended consultation time.

Physical examination: DRE — texture: firm with an irregular nodule situated in the left peripheral zone, while the surrounding tissue remains symmetrically enlarged yet non-tender. General vitals show a blood pressure of 125/89 mmHg alongside a regular cardiac rhythm at 77 beats per minute. Peripheral lymph nodes and abdominal organs reveal no enlargement or masses.

Patient info: civil engineer; Married; Lives with partner.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 4 units / week; exercise Tennis 2x/week; IPSS score: 14/35 (moderate LUTS).

Recent other appointments: Radiology — chest X-ray (routine).
Admin: Patient travels 60+ min by train to clinic; allow buffer.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: NO BIOPSY   p(biopsy) = 0.36
  uncertainty  +/- 0.16 epistemic (95% band 0.05-0.68); among patients I cannot tell apart the outcome was 0.94 of 1.00 mixed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. My criterion answers DEFER.

The criterion: PSA >= 20 ng/mL in a man with a tissue diagnosis: the next step is staging and treatment, not more tissue. In the labelled series this criterion matched the reading urologist in 5 of 6 cases in exactly this situation.

Like Expert 1, I have read ONLY the visible panel — not the mpMRI prose, the PSA trajectory, the
previous notes or the laboratory panel. Departing from me needs a specific finding from a document
somebody actually opened, named out loud; not a restatement of the panel numbers I already used.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 48 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 0.72: PI-RADS 5, PSA 160.0, PSAD 2.635, age 63, DRE Abnormal -> DEFER (clear). He wrote: "Start treating the patent. It does not make sense to not treat this man initially."
  2. distance 0.78: PI-RADS 5, PSA 113.0, PSAD 2.61, age 67, DRE Nodus -> DEFER (clear). He wrote: "Patient has a verified PCa with PSA 113. Start treatment and do I PSMA-PET for further workup."
  3. distance 1.33: PI-RADS 5, PSA 187.0, PSAD 3.26, age 75, DRE Nodus -> BIOPSY (clear). He wrote: "Very High PSA. Most likely metastatic"

PRECEDENT: DEFER (weighted vote 0.23 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 48 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes.
WHAT HE WEIGHS: bx=decisive, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The guideline addresses the risk-adapted matrix for biopsy based on PI-RADS score and PSA density. "linking PI-RADS score (1-2, 3, and 4-5) to PSA-D categories (< 0.10, 0.10-0.15, 0.15-0.20 and > 0.20ng/mL) (Table 5.5) [230]. This risk-adapted matrix table may guide the decision to perform a biopsy." For this patient, the PI-RADS score is 5 and the PSA density is 4.097 ng/mL², which falls into the highest risk category (> 0.20 ng/mL/cc).

WHAT THE EXPERTS' BIDS DO NOT SETTLE
EXPERT-STRUCTURED, I disagree with the suggestion of no biopsy because the guideline suggests a risk-adapted matrix should guide the decision, which is not captured by the panel variables alone. EXPERT-COHORT, your criterion that DEFER based solely on a prior positive biopsy and PSA $\ge 20$ ng/mL does not account for the high PI-RADS score and high PSA density, which the guideline uses in its risk-adapted matrix.

WHAT THE DOCUMENTS MUST SETTLE
previous_notes - the prior biopsy status: Positive means the guideline suggests staging and treatment, not more tissue; if it is unrecorded the indication stands
radiology_report - whether the lesion is compared against an earlier study: unchanged does not support re-sampling, new or larger does
psa_trend - the PSA trend: the guideline suggests the PSA-D category is a significant predictor in the risk-adapted matrix, meaning the current PSA density is decisive here
laboratory_results - the PSA density: the guideline makes decisive here as it places the patient in the highest risk category (> 0.20 ng/mL/cc)
family-history anamnesis - the family-history anamnesis: the guideline suggests family history is a significant predictor in the risk-adapted matrix, meaning this variable must be considered in the risk stratification.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case hinges on whether the high PI-RADS score and PSA density override the prior positive biopsy status, which the EAU guideline suggests should be considered via the risk-adapted matrix.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Determine if the lesion is compared against an earlier study to assess the need for re-sampling.
  psa_trend (get_psa_trend) -> Determine if the PSA trend is significant in the risk-adapted matrix calculation.
  previous_notes (get_previous_notes) -> Determine the prior biopsy status (GRADE, number/dates of biopsies, surveillance plan, and treatment agreement).

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. previous_notes: What is the GRADE (Gleason/ISUP) of the prior biopsy, the number and dates of biopsy sessions, whether the patient is on a SURVEILLANCE protocol with a confirmatory biopsy due, and whether a TREATMENT is already agreed or declined?
  Q2. radiology_report: Is the lesion compared against an earlier study (i.e., is it unchanged, new, or larger)?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
COMPARISON: new
LESION: size 28 x 22 x 20 mm within the left peripheral zone at the base and mid-gland.
psa_trend
The PSA trend shows a rise from 15.3 (Dec 2023) to 190.0 (Feb 2025), with the steepest rise occurring between Sep 2024 (19.1) and Feb 2025 (190.0).
previous_notes
PRIOR GRADE: not recorded
BIOPSY SESSIONS: not recorded
SURVEILLANCE: not recorded
TREATMENT: none recorded

WHAT I DID NOT OPEN
I did not open the laboratory_results because the decision hinges on the risk-adapted matrix which is informed by the PSA density, which is present in the lab results.

WHAT THIS SUPPORTS
FOR sampling this patient now
PI-RADS 5 score from the radiology_report.
PSA density of 4.097 ng/mL/mL from the laboratory_results (implied by the panel data).
The significant PSA trend from the psa_trend document.
AGAINST sampling this patient now
Prior biopsy status is positive, suggesting staging and treatment rather than further tissue sampling.

WHERE THIS LEANS
LEAN: defer

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (clear). Last value 190.00 ng/mL over 4 points spanning 14 months; velocity +141.74 ng/mL per year; doubling time about 3 months.
PROJECTION at 6 months: 720.4 ng/mL, conformal 95% band 206.7-2511.0.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report — the laboratory panel was not opened, so that block is imputed and my band is wider for it; nothing from the previous notes or the PSA series.

SUGGESTION: NO BIOPSY   p(biopsy) = 0.35
  uncertainty  +/- 0.13 epistemic (95% band 0.09-0.61), of which 0.01 comes from values that had to be imputed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 56% of the time over the 25 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  DEFER, p(biopsy)=0.36  ('discuss' tier; weight 1.0)
  EXPERT-FUSION      DEFER, p(biopsy)=0.35  ('supports' tier, fusion_nolab; weight 3.0)
  EXPERT-LIBRARY     DEFER, p(biopsy)=0.23  (k=3 precedents; does not vote)
  EXPERT-COHORT      DEFER  (rule psa_ge_20; does not vote)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: cohort criterion (psa_ge_20) — carried by EXPERT-COHORT.
PANEL ANSWER: NO BIOPSY. It matched the reading urologist in 5 of 6 labelled cases in exactly this situation (prior positive biopsy).

Confidence the trace model expects here: clear. Weights it expects: bx=decisive, fh=noted, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents retrieved by the registrar—radiology\_report, psa\_trend, and previous\_notes—directly address the moderator's questions regarding the prior biopsy status and comparison of the lesion.

ALIGNMENT WITH THE PANEL
The panel protocol concluded NO BIOPSY based on the cohort criterion (PSA $\ge 20$ ng/mL) and the lack of documented prior grade. The registrar's findings, specifically the PSA trend showing a significant rise and the previous notes stating "PRIOR GRADE: not recorded," align with the panel's conclusion by confirming the lack of a documented prior grade.

THE OPEN QUESTIONS, ONE BY ONE
Q1. previous\_notes: The registrar reported that the PRIOR GRADE is not recorded, biopsy sessions are not recorded, surveillance is not recorded, and treatment is not recorded. This leaves the critical information regarding the prior biopsy status unanswered.
Q2. radiology\_report: The registrar reported that the comparison status is "new."

WHAT CARRIES WEIGHT, AND WHY
The most relevant variables according to the EAU guideline are the PI-RADS score (5) and the PSA density ($4.097 \text{ ng/mL}^2$), as these place the patient in the highest risk category. The PSA trend is also highly relevant as it shows a significant rise.

MY SUGGESTION TO THE CHAIR
Given that the prior biopsy status (Q1) remains unrecorded, which is a key factor in the panel's decision, the record is not yet in a state to be definitively decided according to the guideline's risk-adapted matrix.

VERDICT: not-ready | SUGGEST: defer | MISSING: previous_notes

[The conference closes after pass 1: every document on the plan is open; nothing outside the plan is ever opened. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: NO BIOPSY   (confidence: clear)

66y male, PSA 190, PSAD 4.1, PI-RADS 5, prior positive biopsy with unrecorded grade. High PSA and PI-RADS 5 suggest established disease; no prior grade recorded. Decision is to proceed to staging and treatment rather than repeat biopsy.

What carried weight: bx=decisive, age=important, psa=important, vol=noted, psad=noted, pirads=decisive, comorbidity=noted
Sections retrieved: radiology_report, psa_trend, previous_notes
